

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | |
|---|---|-----------------------------------|
| In re Application of: Robert Hugh BRADBURY <i>et al.</i> |) | Confirmation No.: 3653 |
| |) | |
| Application No.: 10/578,663 |) | Group Art Unit: <i>Unassigned</i> |
| |) | |
| Filed: May 9, 2006 |) | Examiner: <i>Unassigned</i> |
| |) | |
| For: QUINAZOLINE DERIVATIVES |) | Date: January 17, 2007 |

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, **Mail Stop Amendment**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97(b)

Citation of Technically Related U.S. Patent Applications

The Examiner's attention is directed to the following technically related U.S. patents or applications of Applicants' assignee:

| Inventor | U.S. Serial No. Filing Date | U.S. Patent No. Issue Date | PCT Publication No. PCT Publication Date |
|------------------|--|---------------------------------------|---|
| Hennequin et al. | 11/443,395 May 31, 2006 | | WO 03/040109 May 15, 2003 |
| Hennequin et al. | 11/443,208 May 31, 2006 | | WO 03/040108 May 15, 2003 |
| Bradbury et al. | 10/554,202 October 24, 2005 | | WO 2004/093880 November 4, 2004 |
| Bradbury et al. | 10/571,851 March 15, 2006 | | WO 2005/026151 March 24, 2005 |
| Bradbury et al. | 10/572,262 March 16, 2006 | | WO 2005/026152 March 24, 2005 |
| Bradbury et al. | 10/857,342 June 1, 2004 | | WO 2005/012290 November 4, 2004 |
| Bradbury et al. | 11/628,011 November 30, 2006 | | WO 2005/118572 December 15, 2005 |

With the exception of the documents listed in the table above in bold (for which a copy was provided with the previously filed Information Disclosure Statement), a copy of the specification and claims for each application, in the form of the published PCT application from which such application was filed is being filed herewith. Consideration of each listed application is earnestly solicited

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request the Examiner to consider this Supplemental Information Disclosure Statement and the documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application. Accordingly, Applicants do not believe a fee is due for filing this Supplemental Information Disclosure Statement.

Copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a

CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R.

§1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP



Date: January 17, 2007
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000

By:

Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

| | | | | | | | |
|---|-----|--|-------------------|--|-------|--------------------------------------|-------------|
| INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449 January 17, 2007 | | | | Attorney Docket No. 056291-5283 | | Application No. 10/578,663 | |
| | | | | Applicants: Robert Hugh BRADBURY et al. | | | |
| | | | | Filing Date: May 9, 2006 | | Group Art Unit: Unassigned | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| Initial | | Document No. | Date | Name | Class | Sub-Class | Filing Date |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | Document No. | Date | Country | Class | Sub-Class | Translation |
| | 1. | WO 2005/012290 | November 4, 2004 | WIPO | | | |
| | 2. | WO 2005/118572 | December 15, 2005 | WIPO | | | |
| | 3. | WO 2006/008526 | January 26, 2006 | WIPO | | | |
| ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./ | | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | |
| | 4. | Ballard et al. "Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics" Bioorg Med Chem Lett. 16(18):4908-4912 (2006) . | | | | | |
| | 5. | Harris et al. "Facile synthesis of 7-amino anilinoquinazolines via direct amination of the quinazoline core" Tetrahedron letters 46(43):7381-7384 (2005) . | | | | | |
| | 6. | Harris et al. "Selective alkylation of a 6,7-dihydroxyquinazoline" Tetrahedron letters 46(45):7715-7719 (2005) . | | | | | |
| | 7. | Hennequin et al. "Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors" Bioorg Med Chem Lett. 16(10):2672-2676 (2006) . | | | | | |
| | 8. | Stamos et al. "Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor" J. Biol. Chem. 277(48):46265-46272 (2002) . | | | | | |
| | 9. | Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997) . | | | | | |
| | 10. | Traxler et al. "Tyrosine kinase inhibitors in cancer treatment (Part II)" Exp. Opin. Ther. Patents 8(12):1599-1625 (1998) . | | | | | |
| | 11. | Tsou et al. "6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity" J. Med. Chem. 44:2719-2734 (2001) . | | | | | |
| | 12. | Vema et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with structure-based studies" Bioorg Med Chem. 11(21):4643-4653 (2003) . | | | | | |
| ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./ | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Examiner | | | | Date Considered | | | |
| /Tamthom Truong/ | | | | 09/05/2008 | | | |
| Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |